Back
Evolving Treatment Landscape in Relapsed and Refractory Multiple Myeloma
Explore evolving clinical considerations in relapsed and refractory multiple myeloma, drawing on recent clinical trial data, real-world evidence, and insights from major scientific meetings, including ASH 2025.
Evolving Treatment Landscape in Relapsed and Refractory Multiple Myeloma
Episodes
All
All
Explore how early-relapse multiple myeloma treatment shifts toward CAR T and bispecifics, weighing high-risk biology, kidney issues, logistics, and infection safety.
Experts weigh how to sequence myeloma therapies, highlighting where antibody-drug conjugates like belantamab fit when CAR-T or bispecific options aren’t feasible.
Early myeloma referral to academic centers helps patients access trials, avoid therapy pitfalls, and stay eligible for earlier CAR-T and bispecifics.
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
5